Aclarion (ACON) vs Sera Prognostics (SERA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Sera Prognostics is the larger company by market cap ($72.0 million vs $3.5 million), about 20.4 times the size, while Aclarion is growing revenue faster (+65.6% vs +5.2%). Aclarion converts more of its revenue into profit, with a net margin of -9551.9% versus -39417.3%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ACON | SERA |
|---|---|---|
| Share price | $1.22 | $1.81 |
| Market cap | $3.52M | $71.98M |
| 1-day change | -13.92% | -4.23% |
| YTD return | — | -38.64% |
| 1-year return | — | -43.96% |
| 5-year return | — | -83.55% |
| EPS (TTM) | $-5.01 | $-0.67 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $75.73K | $81.00K |
| Revenue growth (YoY) | +65.62% | +5.19% |
| Net income (latest FY) | $-7.23M | $-31.93M |
| Gross margin | 9.02% | -102.47% |
| Operating margin | -9312.55% | -45066.67% |
| Net margin | -9551.87% | -39417.28% |
| 52-week high | $9.36 | $3.85 |
| 52-week low | $1.22 | $1.56 |
| Distance from 52-week high | -86.94% | -52.99% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +524.18% | +203.87% |
| Average volume | 34.73K | 27.84K |
| Shares outstanding | 2.88M | 38.80M |
| Employees | 10 | 71 |
| Sector | Health Care | Health Care |
| Industry | Medical Specialities | Medical Specialities |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Sera Prognostics is about 20.4 times larger than Aclarion by market value ($71.98M vs $3.52M).
- Aclarion is more profitable, keeping -9551.9 cents of every revenue dollar as net income versus -39417.3 cents for Sera Prognostics.
- Aclarion grew revenue faster in its latest fiscal year (+65.62% vs +5.19%).
About Aclarion
ACON stock →Aclarion, Inc. operates as a healthcare technology company in the United States.
Health Care · Medical Specialities · 10 employees
About Sera Prognostics
SERA stock →Sera Prognostics, Inc., a women's health company, discovers, develops, and commercializes blood-based biomarker tests, and predictive analytic products and services in the United States. The company develops the PreTRM test, a non-invasive blood test given to a pregnant woman, carrying a single fetus, during weeks 18 through 20 of gestation.
Health Care · Medical Specialities · 71 employees
ACON vs SERA FAQ
Which is bigger, Aclarion or Sera Prognostics?
Sera Prognostics (SERA) is larger, with a market capitalization of $71.98M compared with $3.52M for Aclarion (ACON).
Are Aclarion and Sera Prognostics in the same industry?
Yes. Both are classified in the Medical Specialities industry within the Health Care sector.